FDA approval of Phase 3 trials for MDMA therapy

The FDA’s approval of Phase 3 trials of MDMA therapy for PTSD marked a decisive advance in the effort to bring psychedelic treatment back into sanctioned research. For MAPS, which had spent decades pursuing that goal, the approval suggested that a therapy once associated with counterculture might again be judged through clinical evidence—though it did not yet mean that doctors could prescribe MDMA.

Background and the campaign for clinical research

The approval emerged from the work of the Multidisciplinary Association for Psychedelic Studies, the nonprofit founded by Rick Doblin in 1986 to increase public understanding of psychedelics and support research into their therapeutic uses. Based in Santa Cruz, California, MAPS concentrated its efforts on MDMA as an intervention for people with PTSD. Its project joined a larger revival of psychedelic research, but the regulatory step was especially consequential: it moved MDMA therapy into the most advanced phase of clinical testing described in the book.

The Phase 3 approval

In 2016, the FDA approved MAPS to conduct Phase 3 trials of MDMA for PTSD. The approval was not a finding that the treatment was already established or available by prescription; it authorized the next stage of trials. At the 2017 Psychedelic Science conference, the book presents this milestone as evidence that a once-remote prospect had become tangible. Rick Doblin told a reporter, “We are not the counterculture. We are the culture.”

Breakthrough designation and what remained uncertain

In 2017, the FDA designated MDMA a “breakthrough therapy” for PTSD, clearing the way for an expedited review. The designation strengthened the sense of momentum around the research, but it was not the same as approval for general medical use. At the conference, Doblin’s expectation was still conditional: if Phase 3 results came close to those of Phase 2, the government would presumably have to reschedule MDMA, after which doctors could prescribe it. The account therefore holds the promise and the uncertainty together: regulatory progress had opened a route toward medical use, but the route still depended on trial findings and further government action.

Significance

The Phase 3 approval signaled a change in the institutional standing of psychedelic therapy. MAPS had been established with the improbable aim of restoring psychedelics to scientific and cultural respectability; FDA authorization gave that effort a formal clinical pathway. The later breakthrough designation added momentum, while the conditional language around rescheduling and prescribing made clear that renewed legitimacy was not yet equivalent to settled efficacy or routine treatment.